Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H27N3O7 |
Molecular Weight | 457.4764 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC3=C(C=CC(O)=C3C(=O)C1=C(O)[C@]4(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]4([H])C2)N(C)C
InChI
InChIKey=DYKFCLLONBREIL-KVUCHLLUSA-N
InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
Molecular Formula | C23H27N3O7 |
Molecular Weight | 457.4764 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Minocycline is a tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. Minocycline has many brand names one of them is minocin, Minocin is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci etc. Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species etc. MINOCIN also is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection, etc. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Meningitis due to Neisseria meningitidis. Syphilis caused by Treponema pallidum subspecies pallidum. Yaws caused by Treponema pallidum subspecies pertenue, etc. Minocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Minocycline inhibits protein synthesis by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14723559 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | MINOCIN Approved UseMinocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.7088001E10 |
|||
Curative | MINOCIN Approved UseMinocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.7088001E10 |
|||
Curative | MINOCIN Approved UseMinocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.7088001E10 |
|||
Curative | MINOCIN Approved UseMinocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.7088001E10 |
|||
Curative | MINOCIN Approved UseMinocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.7088001E10 |
|||
Primary | MINOCIN Approved UseMinocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date4.7088001E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.63 μg/mL |
135 mg 1 times / day steady-state, oral dose: 135 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
MINOCYCLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33.32 μg × h/mL |
135 mg 1 times / day steady-state, oral dose: 135 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
MINOCYCLINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Minocycline and benign intracranial hypertension. | 1992 |
|
Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. | 1992 Oct |
|
Minocycline-induced pericardial effusion. | 2000 Jul-Aug |
|
Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. | 2000 Nov |
|
Minocycline-induced hepatitis. | 2000 Oct |
|
Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. | 2000 Oct |
|
Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. | 2000 Oct |
|
Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. | 2000 Oct |
|
Giant cell myocarditis as a manifestation of drug hypersensitivity. | 2000 Sep-Oct |
|
Minocycline-associated lupus-like syndrome with ulnar neuropathy and antiphospholipid antibody. | 2001 |
|
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. | 2001 Apr 15 |
|
Minocycline and Pseudotumor cerebri: The well-known but well-kept secret. | 2001 Aug |
|
Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris. | 2001 Feb |
|
Minocycline hypersensitivity syndrome with hypotension mimicking septic shock. | 2001 Jul-Aug |
|
Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. | 2001 Jun 15 |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
Treatment of vancomycin-resistant enterococcal infections in the immunocompromised host: quinupristin-dalfopristin in combination with minocycline. | 2001 Nov |
|
[Two cases of minocycline-induced vasculitis]. | 2002 Dec |
|
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates. | 2002 Mar |
|
Pseudotumor cerebri secondary to minocycline intake. | 2002 May-Jun |
|
[Bilateral papilledema in young women: two case reports of benign intracranial hypertension?]. | 2002 Oct |
|
Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. | 2002 Oct |
|
ANCA-positive crescentic glomerulonephritis associated with minocycline therapy. | 2003 Aug |
|
Minocycline-induced cutaneous polyarteritis nodosa with antineutrophil cytoplasmic antibodies. | 2003 Jul-Aug |
|
Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. | 2003 Oct |
|
Minocycline inhibits smooth muscle cell proliferation, migration and neointima formation after arterial injury. | 2003 Oct |
|
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. | 2003 Sep 2 |
|
Interstitial pneumonia and hepatitis caused by minocycline. | 2004 Feb |
|
Severe acute myopathy induced by minocycline. | 2004 Feb 15 |
|
Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. | 2004 Mar 3 |
|
Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. | 2004 May 7 |
|
A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. | 2004 Oct |
|
Involvement of mitochondrial potential and calcium buffering capacity in minocycline cytoprotective actions. | 2005 |
|
Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination. | 2005 Jan |
|
Case report and review of minocycline-induced cutaneous polyarteritis nodosa. | 2005 Jun 15 |
|
[Minocycline-induced pleurocarditis and eosinophilic pneumonia: à propos of a case]. | 2005 Mar |
|
Minocycline in neurological diseases. | 2005 Mar |
|
Minocycline-induced vasculitis fulfilling the criteria of polyarteritis nodosa. | 2006 |
|
Additional case of minocycline-induced cutaneous polyarteritis nodosa: comment on the article by Culver et al. | 2006 Oct 15 |
|
Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. | 2007 Apr 15 |
|
Minocycline delays but does not attenuate the course of experimental autoimmune encephalomyelitis in Streptococcus pneumoniae-infected mice. | 2007 Jan |
|
Minocycline-induced cutaneous polyarteritis nodosa. | 2007 Jun |
|
Hyperthyroidism and lupus-like syndrome in an adolescent treated with minocycline for acne vulgaris. | 2007 May-Jun |
|
Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. | 2007 Nov |
|
Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. | 2007 Nov |
|
Minocycline toxicity requiring liver transplant. | 2007 Nov |
|
Role of NF-kappaB and MAPKs in light-induced photoreceptor apoptosis. | 2007 Oct |
|
Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. | 2007 Oct |
|
Minocycline hepatitis. | 2008 Aug |
|
Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. | 2008 Nov |
Patents
Sample Use Guides
For Pediatric Patients above 8 years of Age: usual pediatric dose: Initial dose of 4 mg/kg, then 2 mg/kg administered over 60 minutes every 12 hours, not to exceed the usual adult dose.
Adults: usual adult dose: Initial dose of 200 mg, then 100 mg administered over 60 minutes ever y 12 hours and should not exceed 400 mg in 24 hours.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17119701
It was investigated the minimal inhibitory concentration (MIC) of minocycline on superinfecting microorganisms isolated from the periodontal pocket and the oral cavity of individuals with chronic periodontitis. Isolates of Enterobacteriaceae (n = 25), Staphylococcus spp. (n = 25), Pseudomonas aeruginosa (n = 9) and Candida spp. (n = 25) were included in the study. Minimal inhibitory concentrations (MIC) of minocycline were determined using the Müeller-Hinton agar dilution method. Staphylococcus spp. isolates were the most sensitive to minocycline with a MIC of 8 microg/mL, followed by Enterobacteriaceae with a MIC of 16 microg/mL. The concentration of 16 microg/mL inhibited 96% of Candida spp. isolates. The MIC for 88.8% of the isolates of Pseudomonas aeruginosa was 128 microg/mL. A concentration of 1,000 microg/mL was not enough to inhibit 100% of the tested isolates.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 17:34:33 UTC 2022
by
admin
on
Fri Dec 16 17:34:33 UTC 2022
|
Record UNII |
FYY3R43WGO
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA01AB23
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
||
|
LIVERTOX |
NBK547956
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
||
|
NDF-RT |
N0000007948
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
||
|
WHO-VATC |
QJ01AA08
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
||
|
NDF-RT |
N0000007948
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
||
|
WHO-ATC |
A01AB23
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
||
|
NCI_THESAURUS |
C1595
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
||
|
NDF-RT |
N0000175882
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
||
|
WHO-ATC |
J01AA08
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10118-90-8
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
CHEMBL1434
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
FYY3R43WGO
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
3130
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
DTXSID1045033
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
50694
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
M7553
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | Merck Index | ||
|
FYY3R43WGO
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
Minocycline
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
6980
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | RxNorm | ||
|
C61849
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
SUB08980MIG
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
DB01017
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
77906
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
MINOCYCLINE
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
D008911
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
1813
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY | |||
|
1646
Created by
admin on Fri Dec 16 17:34:33 UTC 2022 , Edited by admin on Fri Dec 16 17:34:33 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
||
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: INTERMEDIATE |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: SUSCEPTIBLE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: IV |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: STREPTOCOCCUS PNEUMONIAE |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: ENTEROBACTERIACEAE, ACINETOBACTER, STAPHYLOCOCCUS AUREUS, VIBRIO CHOLERATE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: HEPATIC IMPAIRMENT |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: STREPTOCOCCUS PNEUMONIAE |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: RESISTANT |
|
||
MIC | BIOLOGICAL |
|
PATHOGEN: STREPTOCOCCUS PNEUMONIAE |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: ORAL |
|
||
Tmax | PHARMACOKINETIC |
|
ROUTE OF ADMINISTRATION: EXTENDED RELEASE TABLET |
|
||
Tmax | PHARMACOKINETIC |
|
DOSAGE FORM: CAPSULE, PELLET FILLED |
|
||
Tmax | PHARMACOKINETIC |
|
DOSAGE FORM: TABLET |
|
||
Biological Half-life | PHARMACOKINETIC |
|
With renal impairment PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: RENAL IMPAIRMENT |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: SUSCEPTIBLE |
|
||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: RESISTANT |
|
||